Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.

GlobeNewsWire • Sep 29, 2026

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.

MarketBeat • Aug 12, 2026

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Apyx Medical Q2 Earnings Call Highlights

Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces.

MarketBeat • Aug 6, 2026

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Apyx Medical (APYX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.09 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.

GlobeNewsWire • Jul 28, 2026

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.

GlobeNewsWire • Jul 23, 2026

Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway

CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.

PRNewsWire • May 27, 2026

New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®

Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach

GlobeNewsWire • May 21, 2026